JP2009542723A5 - - Google Patents

Download PDF

Info

Publication number
JP2009542723A5
JP2009542723A5 JP2009518636A JP2009518636A JP2009542723A5 JP 2009542723 A5 JP2009542723 A5 JP 2009542723A5 JP 2009518636 A JP2009518636 A JP 2009518636A JP 2009518636 A JP2009518636 A JP 2009518636A JP 2009542723 A5 JP2009542723 A5 JP 2009542723A5
Authority
JP
Japan
Prior art keywords
methyl
hydroxy
piperazin
cyclopenta
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009518636A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542723A (ja
JP5266216B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/072885 external-priority patent/WO2008006040A1/en
Publication of JP2009542723A publication Critical patent/JP2009542723A/ja
Publication of JP2009542723A5 publication Critical patent/JP2009542723A5/ja
Application granted granted Critical
Publication of JP5266216B2 publication Critical patent/JP5266216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009518636A 2006-07-06 2007-07-05 Aktプロテインキナーゼ阻害剤としてのヒドロキシル化およびメトキシル化されたシクロペンタ[d]ピリミジン Active JP5266216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81871806P 2006-07-06 2006-07-06
US60/818,718 2006-07-06
PCT/US2007/072885 WO2008006040A1 (en) 2006-07-06 2007-07-05 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013029956A Division JP5836294B2 (ja) 2006-07-06 2013-02-19 Aktプロテインキナーゼ阻害剤としてのヒドロキシル化およびメトキシル化されたシクロペンタ[d]ピリミジン

Publications (3)

Publication Number Publication Date
JP2009542723A JP2009542723A (ja) 2009-12-03
JP2009542723A5 true JP2009542723A5 (enExample) 2010-08-26
JP5266216B2 JP5266216B2 (ja) 2013-08-21

Family

ID=38686743

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009518636A Active JP5266216B2 (ja) 2006-07-06 2007-07-05 Aktプロテインキナーゼ阻害剤としてのヒドロキシル化およびメトキシル化されたシクロペンタ[d]ピリミジン
JP2013029956A Active JP5836294B2 (ja) 2006-07-06 2013-02-19 Aktプロテインキナーゼ阻害剤としてのヒドロキシル化およびメトキシル化されたシクロペンタ[d]ピリミジン
JP2013133983A Pending JP2013177470A (ja) 2006-07-06 2013-06-26 Aktプロテインキナーゼ阻害剤としてのヒドロキシル化およびメトキシル化されたシクロペンタ[d]ピリミジン
JP2014188238A Withdrawn JP2014231530A (ja) 2006-07-06 2014-09-16 Aktプロテインキナーゼ阻害剤としてのヒドロキシル化およびメトキシル化されたシクロペンタ[d]ピリミジン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013029956A Active JP5836294B2 (ja) 2006-07-06 2013-02-19 Aktプロテインキナーゼ阻害剤としてのヒドロキシル化およびメトキシル化されたシクロペンタ[d]ピリミジン
JP2013133983A Pending JP2013177470A (ja) 2006-07-06 2013-06-26 Aktプロテインキナーゼ阻害剤としてのヒドロキシル化およびメトキシル化されたシクロペンタ[d]ピリミジン
JP2014188238A Withdrawn JP2014231530A (ja) 2006-07-06 2014-09-16 Aktプロテインキナーゼ阻害剤としてのヒドロキシル化およびメトキシル化されたシクロペンタ[d]ピリミジン

Country Status (34)

Country Link
EP (4) EP2966065A3 (enExample)
JP (4) JP5266216B2 (enExample)
KR (5) KR101578877B1 (enExample)
CN (2) CN101578273B (enExample)
AR (3) AR061842A1 (enExample)
AT (1) ATE524447T1 (enExample)
AU (1) AU2007269060B2 (enExample)
BR (3) BR122013028012B8 (enExample)
CA (2) CA2656622C (enExample)
CL (1) CL2007001993A1 (enExample)
CO (1) CO6150161A2 (enExample)
CR (1) CR10600A (enExample)
CY (1) CY1112117T1 (enExample)
DK (2) DK2049501T3 (enExample)
ES (3) ES2554228T3 (enExample)
HR (1) HRP20110908T1 (enExample)
HU (1) HUE026237T2 (enExample)
IL (2) IL196028A (enExample)
IN (1) IN2014KN02886A (enExample)
MA (1) MA31655B1 (enExample)
MX (4) MX377920B (enExample)
MY (1) MY147364A (enExample)
NO (1) NO342346B1 (enExample)
NZ (3) NZ597647A (enExample)
PL (2) PL2402325T3 (enExample)
PT (1) PT2049501E (enExample)
RS (1) RS52212B (enExample)
RU (2) RU2478632C2 (enExample)
SG (4) SG185980A1 (enExample)
SI (2) SI2049501T1 (enExample)
TW (2) TW201332994A (enExample)
UA (1) UA95641C2 (enExample)
WO (1) WO2008006040A1 (enExample)
ZA (1) ZA200900070B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
ES2372955T3 (es) 2006-07-06 2012-01-30 Array Biopharma, Inc. Ciclopenta[d]pirimidinas como inhibidores de la proteína cinasa akt.
JP5231411B2 (ja) * 2006-07-06 2013-07-10 アレイ バイオファーマ、インコーポレイテッド Aktプロテインキナーゼ阻害剤としてのジヒドロチエノピリミジン
ATE493418T1 (de) 2006-07-06 2011-01-15 Array Biopharma Inc Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
WO2008115511A1 (en) 2007-03-20 2008-09-25 Peak Biosciences, Inc. Method for therapeutic administration of radionucleosides
NZ582692A (en) 2007-07-05 2012-05-25 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2711692A1 (en) * 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
WO2009089459A1 (en) * 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2009089462A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
JP5512545B2 (ja) 2008-01-09 2014-06-04 アレイ バイオファーマ、インコーポレイテッド Aktタンパク質キナーゼ阻害剤としてのピリミジルシクロペンタン類
CN103403161A (zh) * 2010-12-23 2013-11-20 基因泰克公司 用于治疗新生物的自噬诱导剂和抑制剂组合疗法
RS56759B2 (sr) * 2011-04-01 2024-10-31 Genentech Inc Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima
RU2635193C2 (ru) * 2011-04-01 2017-11-09 Дженентек, Инк. Биомаркеры для прогнозирования чувствительности к противоопухолевой терапии
CA2831932A1 (en) * 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt and mek inhibitor compounds, and methods of use
SI2861582T1 (sl) * 2012-05-17 2016-09-30 Array Biopharma, Inc. Postopek za izdelavo hidroksiliranih ciklopentilpirimidinskih spojin
EP2850200A1 (en) * 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
MX350443B (es) * 2012-05-17 2017-09-06 Genentech Inc Proceso para hacer compuestos de aminoácidos.
CA2873653A1 (en) * 2012-05-17 2013-11-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
HUE051254T2 (hu) * 2012-05-17 2021-03-01 Genentech Inc Egy AKT-gátló pirimidin-ciklopentán vegyület amorf formája, annak kompozíciói és eljárásai
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
KR20150092760A (ko) * 2012-12-07 2015-08-13 더 제너럴 하스피탈 코포레이션 Pi3k/akt 저해제 화합물과 her3/egfr 저해제 화합물의 조합 및 과다증식성 장애의 치료에 있어서의 이의 용도
JP6340162B2 (ja) * 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
MX385726B (es) 2013-11-15 2025-03-18 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano.
BR112017005931B1 (pt) 2014-09-26 2024-04-30 F. Hoffmann-La Roche Ag Processos para preparar um composto de ciclopentil[d]pirimidin-4-il) piperazina e composto de ciclopentil[d]pirimidin-4-il)piperazina
EP4613333A3 (en) 2016-08-10 2025-10-29 F. Hoffmann-La Roche AG Pharmaceutical compositions comprising akt protein kinase inhibitors
EP3532464A4 (en) 2016-10-28 2020-07-08 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
AU2019231689A1 (en) * 2018-03-06 2020-09-24 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
CA3104298A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
WO2020131765A1 (en) 2018-12-19 2020-06-25 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
US20220144821A1 (en) * 2019-01-29 2022-05-12 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Akt inhibitor
EP3946330A1 (en) 2019-03-29 2022-02-09 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
US20220226481A1 (en) * 2019-04-09 2022-07-21 Dana-Farber Cancer Institute, Inc. Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use
CA3137916A1 (en) 2019-05-06 2020-11-12 Ichan School Of Medicine At Mount Sinai Heterobifunctional compounds as degraders of hpk1
JP2023520140A (ja) * 2020-03-17 2023-05-16 江蘇恒瑞医薬股▲ふん▼有限公司 縮合二環系誘導体、その調製方法及びその医薬的応用
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
WO2021254920A1 (en) 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Process for making hydroxylated cyclopentylpyrimidine compounds
US20230286979A1 (en) 2020-07-22 2023-09-14 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate
CN113788834B (zh) * 2021-09-18 2022-11-29 河南奥思恩医药科技有限公司 2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法
WO2023109540A1 (zh) * 2021-12-17 2023-06-22 中国医药研究开发中心有限公司 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
KR20250089532A (ko) 2022-10-17 2025-06-18 아스트라제네카 아베 암 치료를 위한 serd의 조합
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
WO2024160843A1 (en) 2023-01-31 2024-08-08 F. Hoffmann-La Roche Ag Mutant ketoreductase with increased ketoreductase activity as well as methods and uses involving the same
EP4643858A1 (en) 2024-04-29 2025-11-05 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of uterine disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL7112938A (enExample) * 1970-09-30 1972-04-05
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
DE69820989T2 (de) * 1997-01-08 2004-12-09 F. Hoffmann-La Roche Ag Tricyclische benz[e]isoindole und benz[h]isochinoline
ES2152902B1 (es) * 1999-07-27 2001-08-16 Medichem Sa Procedimiento de obtencion de venlafaxina
CA2426440C (en) * 2000-08-18 2011-03-15 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
ATE346064T1 (de) * 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
NZ528635A (en) * 2001-03-30 2006-11-30 King Pharmaceuticals Inc Pharmaceutically active fused thiophene compounds and methods of use
US20050107404A1 (en) * 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
EP1470121B1 (en) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
CN102786482A (zh) * 2003-11-21 2012-11-21 阿雷生物药品公司 Akt蛋白激酶抑制剂
DE602005020611D1 (de) * 2004-04-28 2010-05-27 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
US20090131474A1 (en) * 2005-03-03 2009-05-21 Martino Forino Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
ES2372955T3 (es) * 2006-07-06 2012-01-30 Array Biopharma, Inc. Ciclopenta[d]pirimidinas como inhibidores de la proteína cinasa akt.
JP5231411B2 (ja) * 2006-07-06 2013-07-10 アレイ バイオファーマ、インコーポレイテッド Aktプロテインキナーゼ阻害剤としてのジヒドロチエノピリミジン
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы

Similar Documents

Publication Publication Date Title
JP2009542723A5 (enExample)
RU2478632C2 (ru) Гидроксилированные и метоксилированные циклопента[d]пиримидины в качестве ингибиторов акт протеинкиназ
JP2009542720A5 (enExample)
JP2009542722A5 (enExample)
JP2009542721A5 (enExample)
AP1122A (en) Therapeutically active compounds based on based on based on indazole bioisostere replacement of catechol in PDE4 inhibitors.
CA2731146C (en) 3,4-diarylpyrazoles as protein kinase inhibitors
CN104039798B (zh) 具有蛋白激酶抑制活性的噻吩并[3,2-d]嘧啶衍生物
RU2359967C2 (ru) Производные тиофена и фармацевтическая композиция (варианты)
JP2010533715A5 (enExample)
RU2009103899A (ru) Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ
JP2019537571A5 (enExample)
WO2014181287A1 (en) Heterocyclyl compounds and uses thereof
JP2017525757A5 (enExample)
RU2005137403A (ru) Новые замещенные 3-сера-индолы
IL205501A (en) Preparation of preparations for the treatment of arthritis
JP2003507329A (ja) 3(5)−アミノ−ピラゾール誘導体、それらの製造方法および抗腫瘍薬としてのそれらの使用
JP2010532387A5 (enExample)
RU2006145205A (ru) Терапевтические соединения: пиридин в качестве каркаса
ES2799300T3 (es) Compuestos heteroarilo y su uso como fármacos terapéuticos
JPWO2021170109A5 (enExample)
TWI332838B (en) Antitumor agent comprising an aromatic compound or a salt thereof and use of the aromatic compound or a salt thereof for manufacturing an antitumor agent
RU2018130703A (ru) Новое соединение 2,3,5-замещенного тиофена в качестве ингибитора протеинкиназы
CN100357277C (zh) 1,2,4-三唑衍生物、其制备方法及含有该衍生物的药物组合物
JPWO2018217809A5 (enExample)